Table 1.
Baseline characteristics of patients with chronic CSC in this study. Values are presented as mean ± SD.
| Group | P | ||
|---|---|---|---|
| without PCV formation (n = 36) | Subsequent PCV formation (n = 18) | ||
| Male sex, no. (%) | 32 (88.9%) | 15 (83.3%) | 0.674* |
| Age (years) | 45.4 ± 10.8 | 44.9 ± 7.9 | 0.862† |
| Refractive error (S.E.) | − 0.3 ± 1.7 | − 0.8 ± 1.8 | 0.796‡ |
| LogMAR BCVA | |||
| Initial | 0.10 ± 0.12 | 0.17 ± 0.21 | 0.088‡ |
| SRF resolved | 0.03 ± 0.06 | 0.09 ± 0.08 | 0.001‡ |
| SFCT (μm) | 320.1 ± 92.4 | 325.3 ± 142.1 | 0.851‡ |
| CSC recurrence, no. (%) | 12 (33.3%) | 8 (44.4%) | 0.425** |
| Presence of pachyvessels, no. (%) | 9 (25.0%) | 12 (66.7%) | 0.003** |
| Follow-up duration (months) | 70.8 ± 39.7 | 77.9 ± 26.5 | 0.236‡ |
P value < 0.05 was considered statistically significant. *Fisher's exact test; †independent t test; ‡Mann–Whitney test;
**Chi-square test; CSC, central serous chorioretinopathy; PCV, polypoidal choroidal vasculopathy; S.E., spherical equivalent; logMAR, logarithm of the minimal angle of resolution; SRF, subretinal fluid; SFCT, subfoveal choroidal thickness.